List of works - James P. Allison

Restoring function in exhausted CD8 T cells during chronic viral infection

scientific article

The future of immune checkpoint therapy

scientific article

Enhancement of antitumor immunity by CTLA-4 blockade

scientific article

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

scientific article

Immunologic correlates of the abscopal effect in a patient with melanoma

scientific article (publication date: 8 March 2012)

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

scientific article (publication date: 16 April 1992)

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

scientific article

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

scientific article (publication date: 2 March 2010)

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

scientific article

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

scientific article published on April 2015

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

scientific article

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

scientific article

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

scientific article published on 2 November 2017

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

scientific article

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

scientific article published on 08 February 2012

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

scientific article

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

scholarly article

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

scientific article

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

scientific article

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

scientific article published on 15 June 2006

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

scientific article

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

scientific journal article

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

scholarly article

CTLA-4: new insights into its biological function and use in tumor immunotherapy

scientific article

Cancer classification using the Immunoscore: a worldwide task force

scientific article

The Emerging Role of CTLA-4 as an Immune Attenuator

scientific article published on October 1, 1997

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

scientific article

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

scientific article published on 09 September 2016

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

scientific article published on 28 August 2011

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

scientific article

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

scientific article published on 10 June 2013

Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength

scientific article

Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis

scientific article

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

scientific article

Checkpoint blockade in cancer immunotherapy

scientific article

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

scientific article

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

scientific article published in March 2007

PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells

scientific article

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

scientific article published on 14 June 2016

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

scientific article

Immune modulation in cancer with antibodies

scientific article published on 30 October 2013

Epitope landscape in breast and colorectal cancer

scientific article published in February 2008

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

scientific article published on 9 August 2017

Co-stimulation in T cell responses.

scientific article published on June 1997

Costimulatory regulation of T cell function.

scientific article

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

scientific article published on July 22, 1997

B7x: a widely expressed B7 family member that inhibits T cell activation

scientific article

The B7 family and cancer therapy: costimulation and coinhibition

scientific article published on September 2007

Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells

scientific article published on December 1, 1997

Aire-dependent thymic development of tumor-associated regulatory T cells

scientific article published on March 2013

List of works by James P. Allison

Restoring function in exhausted CD8 T cells during chronic viral infection

The future of immune checkpoint therapy

Enhancement of antitumor immunity by CTLA-4 blockade

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Immunologic correlates of the abscopal effect in a patient with melanoma

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Cancer classification using the Immunoscore: a worldwide task force

The Emerging Role of CTLA-4 as an Immune Attenuator

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength

Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

Checkpoint blockade in cancer immunotherapy

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

Immune modulation in cancer with antibodies

Epitope landscape in breast and colorectal cancer

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Co-stimulation in T cell responses.

Costimulatory regulation of T cell function.

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

B7x: a widely expressed B7 family member that inhibits T cell activation

The B7 family and cancer therapy: costimulation and coinhibition

Lymphoproliferation in CTLA-4–Deficient Mice Is Mediated by Costimulation-Dependent Activation of CD4 + T Cells

Aire-dependent thymic development of tumor-associated regulatory T cells